These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9531059)

  • 21. SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosis.
    Feigen LP; Nicholson NS; King LW; Campion JG; Tjoeng FS; Panzer-Knodle SG
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1191-7. PubMed ID: 8263779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
    Lefkovits J; Malycky JL; Rao JS; Hart CE; Plow EF; Topol EJ; Nicolini FA
    J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
    Yao SK; Ober JC; Ferguson JJ; Maffrand JP; Anderson HV; Buja LM; Willerson JT
    Trans Assoc Am Physicians; 1993; 106():110-9. PubMed ID: 8036734
    [No Abstract]   [Full Text] [Related]  

  • 25. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
    Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
    Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis.
    Tepe G; Schott U; Erley CM; Albes J; Claussen CD; Duda SH
    AJR Am J Roentgenol; 1999 May; 172(5):1343-6. PubMed ID: 10227513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.
    Yamamoto J; Yamashita T; Ikarugi H; Taka T; Hashimoto M; Ishii H; Watanabe S; Kovacs IB
    Blood Coagul Fibrinolysis; 2003 Jan; 14(1):31-9. PubMed ID: 12544726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
    Yasuda T; Gold HK; Leinbach RC; Saito T; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Dec; 16(7):1728-35. PubMed ID: 2123910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
    Yasuda T; Gold HK; Fallon JT; Leinbach RC; Guerrero JL; Scudder LE; Kanke M; Shealy D; Ross MJ; Collen D; Coller BS
    J Clin Invest; 1988 Apr; 81(4):1284-91. PubMed ID: 2832448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
    Graff J; Klinkhardt U; Westrup D; Kirchmaier CM; Breddin HK; Harder S
    Br J Clin Pharmacol; 2003 Sep; 56(3):321-6. PubMed ID: 12919181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis].
    Ottani F; Bresciani B; La Vecchia L; Favero L; Fontanelli A; Galvani M
    Ital Heart J Suppl; 2002 May; 3(5):544-54. PubMed ID: 12064194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
    Pratico D; Murphy NP; Fitzgerald DJ
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1178-85. PubMed ID: 9190851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
    Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M
    Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
    Lucchessi BR; Rote WE; Driscoll EM; Mu DX
    Br J Pharmacol; 1994 Dec; 113(4):1333-43. PubMed ID: 7889289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative studies on the antiplatelet effects of a humanized anti-platelet glycoprotein IIb/IIIa antibody (YM337) and ReoPro under flow conditions.
    Kuwahara M; Sugimoto M; Tsuji S; Miyata S; Nishio K; Kaku S; Suzuki K; Kawasaki T; Yoshioka A
    Thromb Haemost; 1998 Jul; 80(1):28-31. PubMed ID: 9684780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
    Kerins DM; Shuh M; Kunitada S; Fitzgerald GA; Fitzgerald DJ
    J Pharmacol Exp Ther; 1991 Apr; 257(1):487-92. PubMed ID: 1708425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
    Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
    Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine coronary artery.
    Shetler TJ; Bailey BD; Jakubowski JA; Jackson CV
    Thromb Res; 1998 Apr; 90(2):95-100. PubMed ID: 9684763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antithrombocytic effectiveness of magnesium].
    Gawaz M
    Fortschr Med; 1996 Sep; 114(26):329-32. PubMed ID: 8999005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.